Two allocations within the price
Serco’s 292 million dollar cash agreement for QinetiQ’s US business contains two allocations: 237 million dollars for the operating business and 55 million dollars for the net present value of an acquired tax benefit. My starting point is the price inside the company’s highlighted multiple of 9.9 times. Its numerator uses the operating-business consideration alone. The total payment Serco plans to fund with existing cash and committed debt facilities also includes the tax benefit. That difference between operating price and total payment is the first capital allocation question.[1]
The denominator adds at least 3 million dollars of annual cost synergies to Serco’s forecast 2027 underlying operating profit of 21 million dollars. The disclosed calculation divides 237 million dollars by the sum of those amounts. Removing the savings gives a higher earnings multiple for the same operating-business price. The 9.9 times figure therefore incorporates more than the target’s standalone earnings: it already includes the intended efficiency of the combination. That is the key assumption inside management’s acquisition case.[1]
The tax asset changes the time dimension as well. Serco expects the 55 million dollar present value to represent more than 100 million dollars of cash tax savings over 12 years. Adding that long-term total to first-year operating earnings would combine benefits from different periods into one apparent return. A separate allocation to the tax benefit has an economic rationale; retaining that value depends on the anticipated tax savings materialising. Operating earnings and lower tax payments are different cash channels.[1]
The entry cost of savings
The savings also have an entry cost. Serco disclosed approximately 9 million dollars of acquisition and integration expenses, excluded from the 9.9 times calculation. Its target date for annual synergies of at least 3 million dollars is 2028. Placing those amounts alongside each other exposes the timing risk of spending cash before obtaining the annual benefit. Even a one-off integration expense belongs in the funding requirement. Judging success through adjusted earnings alone obscures the interval during which that capital remains committed.[1]
The acquisition’s defence extends beyond reducing expenses. Serco emphasises the engineering and technology capabilities of approximately 800 employees, customer access and greater scale in US defence. If a broader customer base generates additional business, the narrow cost-synergy calculation could understate the total benefit. The announcement assigns no separate revenue-synergy amount to that plausible alternative. I treat strategic access as valuable optionality, while keeping it distinct from realised earnings and from the specifically quantified cost savings.[1]
The capital timetable becomes clear in two management targets: Serco expects underlying earnings-per-share accretion in 2028, the first full year of ownership, and a return on invested capital meeting its weighted average cost of capital in the third full year. The first asks about earnings per share; the second asks about the productivity of committed capital. I give greater weight to the latter because it connects the funded payment with benefits spread across years. Regulatory approvals, integration expenditure and realised cost savings are concrete milestones for that calculation. Today’s 9.9 times incorporates management’s assumption that those milestones are achieved.[1]